Methylenetetrahydrofolate reductase C677T genetic polymorphisms and risk of leukaemia among the North Indian population

Cancer Epidemiology

Volumn 36, Issue 4, 2012, Pages

  Hussain, Syed Rizwan ^a   Naqvi, Hena ^a   Raza, Syed Tasleem ^a   Ahmed, Faisal ^a   Babu, Sunil G ^b   Kumar, Ashutosh ^c   Zaidi, Zeashan Haider ^a   Mahdi, Farzana ^a  

^a Era's Lucknow Medical College and Hospital   (India)

^b BABASAHEB BHIMRAO AMBEDKAR UNIVERSITY   (India)

^c KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

ALL; AML; CLL; CML; Folic acid; Genetic polymorphism; MTHFR

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2);

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RISK; CHILD; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; ETHNOGRAPHY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHOOL CHILD;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIA; LEUKEMIA; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; YOUNG ADULT;

EID: 84863498117     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2012.02.008     Document Type: Article

References (32)

1. Giovannucci E. Epidemiologic studies of folate and colorectal neoplasia. A review. J Nutr 2002, 132:2350S-2355S.
2. Smith M.T, Zhang L. Biomarkers of leukemia risk: benzene as a model. Environ Health Perspect 1998, 106(Suppl. 4):937-946.
3. Barbosa C.G., Souza C.L., Neto J.P.M., Arruda M.G.B., Barreto J.H., Reis M.G., et al. Methylenetetrahydrofolate reductase polymorphisms in myeloid leukemia patients from Northeastern Brazil. Genet Mol Biol 2008, 31:29-32.
4. Robien K., Ulrich C.M. 5,10-Methylenetetrahydrofolate reductase Polymorphisms and leukemia risk: a HuGE minireview. Am J Epidemiol 2003, 157:571-582.
5. Blount B.C., Mack M.M., Wehr C.M. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage. Proc Natl Acad Sci U S A 1997, 94:3290-3295.
6. Dianov G.L., Timchenko T.V., Sinitsina O.I., Kuzminov A.V., Medvedev O.A., Salganik R.I. Repair of uracil residues closely spaced on the opposite strands of plasmid DNA results in double-stranded break and deletion formation. Mol Gen Genet 1991, 225:448-452.
7. Zingg J.M., Jones P.A. Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis. Carcinogenesis 1997, 18:869-882.
8. Shane B. Folate metabolism. Folic acid metabolism in health and disease 1990, 65-78. Willey-Liss, New York. M.F. Picciano, E.L.R. Sokstad, J.F. Gregory (Eds.).
9. Lucock M. Folic acid: nutritional biochemistry, molecular biology, and role in disease processes. Mol Genet Metab 2000, 71:121-138.
10. Homberger A., Linnebank M., Winter C., Willinbring H., Marquardt T., Harms E., et al. Genomic structure and transcript variants of the human methylenetetrahydrofolate reductase gene. Eur J Hum Genet 2000, 8:725-729.
11. Botto L.D., Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol 2000, 151:862-877.
12. Krajinovic M., Labuda D., Richer C., Karimi S., Sinnett D. Susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood 1999, 93:1496-1501.
13. Matsuo K., Suzuki R., Hamajima N., Ogura M., Kagami Y., Taji H., et al. Association between polymorphisms of folate and methionine-metabolizing enzymes and susceptibility to malignant lymphoma. Blood 2001, 97:3205-3209.
14. Song C., Xing D., Tan W., Wei Q., Lin D. Methylenetetrahydrofolate reductase polymorphisms increase risk of esophageal squamous cell carcinoma in a Chinese population. Cancer Res 2001, 61:3272-3275.
15. Campbell I.G., Baxter S.W., Eccles D.M., Choong D.Y. Methylenetetrahydrofolate reductase polymorphism and susceptibility to breast cancer. Breast Cancer Res 2002, 4:R14.
16. Chen J., Giovannucci E., Kelsey K., Rimm E.B., Stampfer M.J., Colditz G.A., et al. A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res 1996, 56:4862-4864.
17. Curtin K., Bigler J., Slattery M.L., Caan B., Potter J.D., Ulrich C.M. MTHFR C677T and A1298C polymorphisms: diet, estrogen, and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 2004, 13:285-292.
18. Oliveira K.C., Bianco B., Verreschi I.T., Guedes A.D., Galera B.B., Galera M.F., et al. Prevalence of the polymorphism MTHFR A1298C and not MTHFR C677T is related to chromosomal aneuploidy in Brazilian Turner Syndrome patients. Arq Bras Endocrinol Metab 2008, 52:1374-1381.
19. Wei J., Hemmings G.P. Allelic association of the MTHFR gene with schizophrenia. Mol Psychiatry 1999, 4:115-116.
20. Qian X., Lu Z., Tan M., Liu H., Lu D. A meta-analysis of association between C677T polymorphism in the methylenetetrahydrofolate reductase gene and hypertension. Eur J Hum Genet 2007, 15:1239-1245.
21. Skibola C.F., Smith M.T., Kane E., Roman E., Rollinson S., Cartwright R.A., et al. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci U S A 1999, 96:12810-12815.
22. Robien K., Ulrich C.M., Bigler J., Yasui Y., Gooley T., Bruemmer B., et al. Methylenetetrahydrofolate reductase genotype affects risk of relapse after hematopoietic cell transplantation for chronic myelogenous leukemia. Clin Cancer Res 2004, 10:7592-7598.
23. Moon H.W., Kim T.Y., Oh B.R., Min H.C., Cho H.I., Bang S.M., et al. MTHFR 677CC/1298CC genotypes are highly associated with chronic myelogenous leukemia: a case-control study in Korea. Leuk Res 2007, 31:1213-1217.
24. Hur M., Park J.Y., Cho H.C., Lee K.M., Shin H.Y., Cho H.I. Methylenetetrahydrofolate reductase A1298C genotypes are associated with the risks of acute lymphoblastic leukaemia and chronic myelogenous leukaemia in the Korean population. Clin Lab Haematol 2006, 28:154-159.
25. Deligezer U., Akisik E., Dalay N. Genotyping of the MTHFR gene polymorphism, C677T in patients with leukemia by melting curve analysis. Mol Diagn 2003, 7:181-185.
26. Wilcken B., Bamforth F., Li Z., Zhu H., Ritvanen A., Renlund M., et al. Geographical and ethnic variation of the 677C-T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide. J Med Genet 2003, 40:619-625.
27. Almawi W.Y., Finan R.R., Tamim H., Daccache J.L., Irani-Hakime N. Differences in the frequency of the C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene among the Lebanese population. Am J Hematol 2004, 76:85-87.
28. Boduroglu K., Alikasifoglu M., Anar B., Tuncbilek E. 677→CT mutation on the methylenetetrahydrofolate reductase gene is not a risk factor for neural tube defects in Turkey. Arch Dis Child Fetal Neonatal Ed 1998, 78:F235. [Letter].
29. Matthew F.R., Gabrielle S.S., Allinson R., Matutes E., Catovsky D., Houlston R.S. MTHFR polymorphisms and risk of chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev 2004, 13:2268-2270.
30. Vahid P., Farnaz R., Zaker F., Farzaneh A., Parisa R. Methylenetetrahydrofolate reductase gene polymorphisms and risk of myeloid leukemia. Labmedicine 2010, 41:490-494.
31. Chiusolo P., Reddiconto G., Cimino G., Sica S., Fiorini A., Farina G., et al. Methylenetetrahydrofolate reductase genotypes do not play a role in acute lymphoblastic leukemia pathogenesis in the Italian population. Hematologica 2004, 89:139-144.
32. Azza M., Kamel, Heba S.M., Gamal T.E., Rong R.B., Kishor G.B. Synergistic effect of methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphism as risk modifiers of pediatric acute lymphoblastic leukemia. J Egypt Natl Cancer Inst 2007, 19:96-105.